Literature DB >> 2438065

Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy.

B L Samuels, N J Vogelzang, B J Kennedy.   

Abstract

Vascular toxicity following the use of vinblastine, bleomycin, and cisplatin (VBP) combination chemotherapy has been described. This report gives details of 5 patients who suffered acute life-threatening vascular events following such a chemotherapy regimen for germ cell tumors. In 3 of the cases no evidence of tumor was found at autopsy. Both an acute and a long-term vascular toxicity were seen. Large artery vascular disease may result from synergistic toxicity of the drugs comprising the regimen. These cases, with an additional 16 collected from the literature, suggest that major vascular disease is a significant side-effect of the VBP regimen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438065     DOI: 10.1007/bf00252982

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  Raynaud's phenomenon of a single digit following local intradermal bleomycin sulfate injection.

Authors:  E A Smith; F E Harper; E C LeRoy
Journal:  Arthritis Rheum       Date:  1985-04

2.  Coronary artery disease after treatment with bleomycin and vinblastine.

Authors:  N J Vogelzang; D H Frenning; B J Kennedy
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

3.  Fatal coronary artery fibrosis after treatment with bleomycin, vinblastine, and cis-platinum.

Authors:  D C Bodensteiner
Journal:  South Med J       Date:  1981-07       Impact factor: 0.954

4.  Long-term treatment with cis-dichlorodiammineplatinum(II)-vinblastine-bleomycin: possible association with severe coronary artery disease.

Authors:  G S Edwards; M Lane; F E Smith
Journal:  Cancer Treat Rep       Date:  1979-04

5.  Letter: Myocardial infarction: a complication of vincristine treatment?

Authors:  G Somers; M Abramov; M Witter; J P Naets
Journal:  Lancet       Date:  1976-09-25       Impact factor: 79.321

6.  Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma.

Authors:  C Teutsch; A Lipton; H A Harvey
Journal:  Cancer Treat Rep       Date:  1977-08

7.  Raynaud's phenomenon after bleomycin treatment.

Authors:  D P Chernicoff; R M Bukowski; J R Young
Journal:  Cancer Treat Rep       Date:  1978-04

8.  Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.

Authors:  N J Vogelzang; J L Torkelson; B J Kennedy
Journal:  Cancer       Date:  1985-12-15       Impact factor: 6.860

9.  Acute vascular episodes associated with therapy for carcinomas of the upper aerodigestive tract with bleomycin, vincristine, and cisplatin.

Authors:  L J Kukla; W P McGuire; T Lad; M Saltiel
Journal:  Cancer Treat Rep       Date:  1982-02

10.  Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.

Authors:  M B Kahaleh; I Osborn; E C LeRoy
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

View more
  19 in total

Review 1.  Comparative tolerability of chemotherapy regimens for germ cell cancer.

Authors:  S Culine; J P Droz
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer.

Authors:  S W Hansen
Journal:  BMJ       Date:  1990-02-24

3.  Autonomic neuropathy after cisplatin based chemotherapy.

Authors:  P Richardson; B M Cantwell
Journal:  BMJ       Date:  1990-06-02

Review 4.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 5.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 6.  Long-term complications of chemotherapy for germ cell tumours.

Authors:  Uzair B Chaudhary; Jason R Haldas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Case report 669: Osteonecrosis of bone associated with intraarterial therapy using cisplatin.

Authors:  P Wuisman; R Erlemann; A Roessner; A Bosse; C Kusniez-Glaz
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

Review 8.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

9.  Long-term sequelae of treatment for testicular germ cell tumours.

Authors:  D Bissett; L Kunkeler; L Zwanenburg; J Paul; C Gray; I R Swan; D J Kerr; S B Kaye
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

10.  Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect.

Authors:  S Sleijfer; T W van der Mark; H Schraffordt Koops; N H Mulder
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.